

powerful data-mining tool to sort various factors into meaningful groups. Recently, cluster analysis has been adopted for research of sleep breathing disorders. However, no one has adopted to predict CPAP adherence. In this study, we aimed to explore the usefulness of cluster analysis to predict CPAP adherence using the diagnostic PSG parameters and patients' characteristics.

Methods: The study design was a retrospective observational multi-center study including 5 certified sleep centers in Japan. For 2 years from 2017, 1133 patients who were diagnosed with OSA with in-lab PSG and newly initiated CPAP therapy were enrolled. We performed cluster analysis using the K-means clustering. Variables for clustering were determined by several sleep physicians among PSG parameters and patients' characteristics. We assessed CPAP adherence for 90 days and 365 days after CPAP initiation in each created cluster. We adopted CMS criteria for good CPAP adherence, which is, more than four hours of use on 70% of nights.

Results: Cluster analysis classified 5 clusters. A significant difference in CPAP adherence for 90 days and 365 days was seen among 5 clusters with a test of independence ($p=0.001$, $p=0.005$, respectively). The cluster presenting moderate obese, very high AHI and ODI, and apnea predominant indicated good adherence, whereas the cluster presenting morbid obese, very high AHI and ODI, sustained severe hypoxia, younger age, and daytime sleepiness indicated poor adherence according to the post-hoc Chi-square test.

Conclusion: Cluster analysis successfully distinguished the different CPAP adherence and identified a combination of OSA patients' profiles. Thus, cluster analysis would be a useful tool for predicting long-term CPAP adherence.

Support (If Any):

0758

BEHAVIORAL DETERMINANTS OF PAP USE IN VETERANS WITH COMISA: RESULTS OF A RANDOMIZED TRIAL

Bronson Barretto¹, Jennifer Martin², Constance Fung², Joseph Dzierzewski³, Carl Stepnowsky⁴, Yeonsu Song⁵, Michelle Zeidler², Monica Kelly², Daniel Enamorado¹, Jody Schnurrenberger⁶, Karen Josephson¹, Michael Mitchell¹, Cathy Alessi²

VA Greater Los Angeles Healthcare System ¹ VA Greater Los Angeles Healthcare System and University of California, Los Angeles ² Virginia Commonwealth University ³ VA San Diego Healthcare System and University of California, San Diego ⁴ University of California, Los Angeles ⁵ University of Southern California ⁶

Introduction: Nonadherence to positive airway pressure (PAP) therapy is common in comorbid insomnia and obstructive sleep apnea (COMISA). We previously reported a novel behavioral treatment for COMISA which improves both PAP adherence and sleep. Our current goal was to assess whether improvements in PAP self-efficacy, knowledge, and decisional balance (targets of treatment) are associated with improvements in PAP use and sleep quality. We also collected participants' perceptions of benefits and challenges of PAP during intervention.

Methods: 125 veterans (96% men, 39% non-Hispanic white, 24% Black, 17% Hispanic/Latino) with COMISA were randomized to a 5-week intervention integrating behavioral insomnia therapy with a PAP adherence program versus general sleep education (control). Objective PAP use data and Pittsburgh Sleep Quality Index (PSQI) were collected over 6 months. Three behavior change subscales (PAP Self-Efficacy [PAP-SE], Decisional Balance Index [DBI], Knowledge [KNOW]) were administered at 6-months. Weekly self-report of participant-perceived benefits and challenges of PAP use

were collected among intervention participants. Subscale scores, PAP use and PSQI were compared between intervention and control, and associations were tested. Change in mean number of benefits and challenges of PAP use were also tested (all analyses intent-to-treat).

Results: At 6-months, compared to controls, intervention participants had higher scores on all three subscales: PAP-SE (4.1 intervention versus 3.5 control, respectively), DBI (8.3, 0.9) and KNOW (10.5, 9.6, all $p<.05$). Intervention participants had more PAP use and lower (better) PSQI scores at 6-months (all $p<.05$). In the total sample, PAP use and PSQI correlated with PAP-SE ($r=.52$ PAP use, $r=-.27$ PSQI, respectively), DBI ($r=.49$, $-.35$) and KNOW ($r=.43$, $-.21$; all $p<.05$). Among intervention participants, perceived benefits of PAP increased over time (4.3 at week 2, 5.8 at week 4, respectively), and challenges decreased (3.7, 2.3; all $p<.05$).

Conclusion: Behavioral treatment for COMISA improves behavioral determinants of PAP use, which is associated with improvements in PAP use and sleep quality. In addition, with treatment, perceived benefits of PAP increase and challenges decrease. These findings suggest improvements in self-efficacy, knowledge and perceived benefits of PAP are important mechanisms through which behavioral interventions improve PAP use in older adults with COMISA.

Support (If Any): VAHSRD (IIR12-353-Alessi, RCSA20-191-Martin) and NIH (NHLBI K24HL143055-Martin, NIA K23AG049955-Dzierzewski)

0759

A REAL WORLD STUDY ASSESSING PATIENT SATISFACTION IN THE PRIMARY CARE SETTING IN RELATION TO EXCESSIVE DAYTIME SLEEPINESS IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA

Sairam Parthasarathy¹, Danielle Hyman², James Doherty³, Ragy Saad³, Jerry Zhang³, Susan Morris², Lev Eldemir⁴, Benjamin Fox⁵, Mai Ka Ying Vang⁴, Jessica Schroeder⁵, Nell Marshall⁵, Gregory Parks³

University of Arizona ¹ Formerly Jazz Pharmaceuticals ² Jazz Pharmaceuticals ³ Formerly Evidation Health ⁴ Evidation Health ⁵

Introduction: Excessive daytime sleepiness (EDS) is common in obstructive sleep apnea (OSA), despite positive airway pressure (PAP) therapy. These analyses evaluated EDS prevalence and its relationship with satisfaction with care in participants with OSA receiving OSA care in a primary care setting.

Methods: US residents (aged ≥ 18 years, self-reported physician OSA diagnosis [1/1/2015–3/31/2020]) completed a survey in Evidation Health's Achievement app assessing Epworth Sleepiness Scale (ESS), specialties of healthcare providers (HCPs) treating OSA, PAP usage, and satisfaction with HCPs and overall OSA care. Self-reported PAP use was categorized: nonuse, nonadherent (<4 h/night, <5 d/wk), intermediate (4 – 6 h/night, ≥ 5 d/wk), or highly-adherent (≥ 6 h/night, ≥ 5 d/wk) (PAP-adherent=intermediate+highly-adherent groups). Linear modeling assessed the relationship between PAP use and ESS score; logistic regression assessed impacts of PAP adherence and EDS on satisfaction with care. P-values are uncontrolled for multiplicity.

Results: Participants (N=2289) were 50.3% female; 82.5% White; 44.8 ± 11.1 years old (mean \pm SD); with BMI 35.4 ± 8.7 kg/m 2 ; 42.5% had EDS (ESS >10). OSA was primarily managed by sleep specialists (43.5%), general practitioners (GPs) (42.5% [28.9% saw a GP only; 13.6% saw a GP and a specialist/pulmonologist]), and/or pulmonologists (18.0%). Among participants with OSA

managed by a GP only (n=662), proportions (95% CI) with EDS were: PAP nonuse (49% [42.8–54.9]), nonadherent (47% [31.5–63.2]), intermediate (47% [33.4–60.8]), and highly-adherent (35% [29.3–39.9]). Linear modeling (PAP users; n=398) showed an additional h/night of PAP use was associated with lower ESS scores (estimate [SE], -0.26 [0.13]; P<0.05); logistic regression showed association between PAP adherence and higher satisfaction with HCPs (adjOR=2.26; 95% CI=1.09–4.70; P<0.05) and OSA care (adjOR=1.58; 95% CI=0.75–3.36; P>0.05). There was an association between presence of EDS and lower satisfaction with their HCPs (adjOR=0.62; 95% CI=0.39–0.99; P<0.05) and OSA care (adjOR=0.49; 95% CI=0.31–0.79; P<0.05).

Conclusion: In a real-world population of participants with OSA receiving OSA care from GPs, EDS was common, even among highly-adherent PAP users. ESS scores were generally lower with increasing PAP adherence. PAP adherence was associated with increased satisfaction with their HCPs; EDS was associated with lower satisfaction with HCPs and overall OSA care.

Support (If Any): Jazz Pharmaceuticals

0760

EXCESSIVE DAYTIME SLEEPINESS, POSITIVE AIRWAY PRESSURE, AND PATIENT SATISFACTION WITH MULTIPLE ASPECTS OF CARE IN A REAL-WORLD POPULATION WITH OBSTRUCTIVE SLEEP APNEA

Sairam Parthasarathy¹, Danielle Hyman², James Doherty³, Ragy Saad³, Jerry Zhang³, Susan Morris², Lev Eldemir⁴, Benjamin Fox⁵, Mai Ka Ying Vang⁴, Jessica Schroeder⁵, Nell Marshall³, Gregory Parks³

University of Arizona ¹ Formerly Jazz Pharmaceuticals ² Jazz Pharmaceuticals ³ Formerly Evidation Health ⁴ Evidation Health ⁵

Introduction: Excessive daytime sleepiness (EDS) is common in patients with obstructive sleep apnea (OSA) and can persist despite use of positive airway pressure (PAP) therapy. These analyses assessed relationships between EDS, PAP use, and patient satisfaction across several aspects of OSA care in a real-world population with OSA.

Methods: US residents (aged ≥18 years, self-reported physician OSA diagnosis [1/1/2015–3/31/2020]) completed a survey in Evidation Health's Achievement app assessing Epworth Sleepiness Scale (ESS), PAP usage, and satisfaction with care. Self-reported PAP use was categorized as nonuse, nonadherent (<4 h/night; <5 d/wk), intermediate (4–6 h/night, ≥5 d/wk), or highly adherent (≥6 h/night, ≥5 d/wk) (PAP-adherent=intermediate and highly adherent groups). Logistic regression models assessed impacts of PAP adherence and EDS on satisfaction with care across 7 domains. P-values are uncontrolled for multiplicity (nominal).

Results: Among all participants (N=2289; 50.3% female, 82.5% White, 44.8±11.1 years old [mean±SD], 35.4±8.7 kg/m² body mass index [mean±SD]), 42.5% had EDS (ESS>10). PAP use was: nonuse (n=700), nonadherent (n=153), or adherent (n=1436; intermediate n=225, high n=1211). Within these subgroups, the proportions (95% CI) with EDS were: nonuse (47% [43.7–51.1]), nonadherent (52% [44.4–60.2]), intermediate (53% [46.4–59.4]), and highly adherent (36% [33.7–39.1]). Logistic regression (using data from PAP users) showed a positive association of PAP adherence with satisfaction with PAP (OR [95% CI]: 5.43 [3.73–7.90]); OSA treatment effectiveness (3.56 [2.48–5.12]); OSA symptom management (3.15 [2.17–4.57]); coordination of OSA care (2.60 [1.82–3.72]); and education from their healthcare provider on the impact of OSA on cardiovascular health (1.62 [1.13–2.35]), importance of using PAP

(1.7 [1.15–2.52]), or availability of prescription drugs to treat OSA symptoms (1.55 [1.06–2.26]). The presence of EDS was associated with lower patient satisfaction in nearly all domains examined (ORs ranged from 0.44–0.62 across 6 of 7 domains).

Conclusion: EDS was common in this real-world population with OSA, even among participants who were highly adherent PAP users. PAP adherence was associated with higher patient satisfaction across all care domains; the presence of EDS was associated with lower patient satisfaction across 6 of 7 domains.

Support (If Any): Jazz Pharmaceuticals

0761

ADAPTABILITY OF THE TREATING OBSTRUCTIVE SLEEP APNEA USING TARGETED HYPOGLOSSAL NERVE STIMULATION (OSPREY) TRIAL

Ofer Jacobowitz¹, Alan Schwartz², Eric Lovett³, Giovanni Ranuzzi³, Atul Malhotra⁴

ENT and Allergy Associates ¹ University of Pennsylvania Perelman School of Medicine ² LivaNova PLC ³ Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California San Diego ⁴

Introduction: With few exceptions, clinical trials of hypoglossal nerve stimulation (HGNS) for obstructive sleep apnea (OSA) are single-arm, open-label studies sometimes followed by short-term, unblinded, randomized withdrawal. By contrast, the THN3 study was a parallel-arm, randomized, controlled trial (RCT) of targeted HGNS (THN) in moderate to severe OSA, and provided higher-level evidence of HGNS safety and efficacy. Despite generating strong evidence, conventional RCTs are risky due to their inherent inflexible designs. We therefore launched a confirmatory THN RCT (OSPREY) with an adaptive, Bayesian “Goldilocks” design that optimize its sample size dynamically, yet achieve high-confidence results.

Methods: Four scenarios were simulated within the OSPREY design framework (randomized 2:1 Treatment:Control) for the primary endpoint of apnea-hypopnea index (AHI) response rate (RR): nominal with results equal to those of THN3 (Treatment AHI RR 52%/Control AHI RR 20%), improved Treatment RR (63%/20%), worsened Treatment RR (41%/20%) and null [Treatment RR=Control RR] (20%/20%). Each scenario was simulated 10 times with 10,000 simulations of each interim analysis. Subject outcomes were determined by randomly drawing from a binomial distribution with the relevant AHI RR. Interim analyses in OSPREY begin at 50 randomized subjects and repeat every 20 additional subjects to the maximum sample size of 150, with opportunities for early success and futility at each milestone to generate high-confidence results from an optimal sample size. OSPREY assesses secondary endpoints including quality of life inventories (Epworth Sleepiness Scale; Functional Outcomes of Sleep Questionnaire; EQ-5D, SF-6D and PROMIS sleep questionnaires) and oximetry metrics (Oxygen Desaturation Index, %sleep time below 90% oxygen saturation). Previous results suggest secondary endpoints will be adequately powered at the final sample size determined by AHI RR.

Results: Simulations produced the following outcomes formatted as [scenario: randomized sample size, overall success rate, probability of early success, mean success probability]: null: 150, 0%, 0%, 2.47%; nominal: 130-150, 100%, 80%, 95.3%; improved: 90-130, 100%, 100%, 98.9%; worsened: 150, 100%, 0%, 68.6%.

Conclusion: OSPREY is uniquely able to adapt to various Treatment/Control response scenarios and should provide high-confidence confirmation of the safety and efficacy of THN therapy in moderate to severe OSA.

Support (If Any): LivaNova